

Centre Scientifique de Monaco, 8 quai Antoine 1er, 98000 MONACO
+377.97.77.44.15 – vpicco@centrescientifique.mc

Vincent PICCO

Chargé de Recherche, “Mécanismes de Résistance aux Thérapies Ciblées”
team, Medical Biology Department, Centre Scientifique de Monaco

D.O.B. 8th august 1980

WORK EXPERIENCE

- Jun. 2013 – Jan. 2014* Postdoc, “Mécanismes de résistances aux thérapies ciblées” team (Dir. Gilles Pagès), Centre Scientifique de Monaco
- Jan. 2009 – May 2013* Postdoc, “Angiogenèse Normale et Pathologique” team (Dir. Gilles Pagès), IRCAN, Nice.

EDUCATION

- Sept. 2005 – Nov. 2008* **PhD in Molecular and Cellular Biology** (ED85, Université Nice-Côte d’Azur), “**Specification of Progenitors during the embryonic development of the ascidian *Ciona intestinalis*”**
UMR7009 CNRS/UPMC Developmental Biology Lab, Villefranche-sur-mer
- Sept. 2002 – Jul. 2005* **Master degree in Health and Life Science, Molecular en Genetics specialisation**, Nice-Sophia Antipolis University

EXPERTISE

Cancer, Developmental Biology, Intracellular Signalisation, Cell Migration, Cellular and Organismal Response to Environmental Stress, DNA Damage Response, Telomere Biology, Predictive and Prognosis Markers in Cancer, Targeted Therapies, Tumoral Angiogenesis.

SKILLS

Laboratory techniques	Biochemistry, Molecular Biology, Cell Culture, Micro-injection and Micro-dissection, Confocal and Epifluorescence Imaging, Automated Image Analysis.
Foreign Languages	English (fluent), Italian, basic Spanish.
Informatics Software	Word, Excel, Powerpoint, Photoshop, Illustrator, ImageJ, Cell Profiler, Ilastik

PUBLICATIONS

ORIGINAL ARTICLES

- 1. The antiangiogenic compound Axitinib demonstrates a low toxicity and anti-tumoral effects against medulloblastoma.** Pagnuzzi-Boncompagni M *, Picco V *, Vandenberghe A, Grépin R, Planas-Bielsa V, Martial S, Vial V, Durivault J, Doyen J, Claren A, Gavard J, Pagès G. **In prep.**
- 2. VEGFC: An unexpected negative regulator of pediatric medulloblastoma aggressiveness.** Comoglio Y, Penco-Campillo M, Feliz Morel AJ, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi-Boncompagni M, Morott A2, Burel-Vandenbos F, Selby M, Clifford S, Claren A,5, Doyen J, Picco V, Martial S, Pagès G. **Submitted**
- 3. AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.** Brolih S*, Parks SK*, Vial V, Durivault J, Mostosi L, Pouysségur J, Pagès G, Picco V.[#] BMC Cancer 2018
- 4. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.** Cormerais Y, Pagnuzzi M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe M F, Pagès G, Pouyssegur J, Picco V.[#] J Cell Mol Med **2017**

- 5. The c-Jun N-terminal kinase prevents oxidative stress induced by UV and thermal stresses in corals and human cells.** Courtial L *, Picco V *, Grover R, Cormerais Y, Rottier C, Labbe A, Pagès G, Ferrier-Pagès C. Sci Rep **2017**
- 6. Validation of commercial ERK antibodies against the ERK orthologue of the scleractinian coral *Stylophora pistillata*.** Courtial L*, Picco V **, Pagès G, Ferrier-Pagès C. F1000Res **2017**
- 7. ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2.** Picco V, Coste I, Giraud-Panis M-J, Renno T, Gilson E and Pagès G. Oncotarget **2016**
- 8. Telomeric Repeat-Binding Factor 2: a marker for survival and anti-EGFR efficacy in Oral Carcinoma.** Picco V *, Benhamou Y *, Raybaud H, Sudaka A, Chamorey E, Brolih S, Martino Monteverde M, Merlano M, Lo Nigro C, Ambrosetti D and Pagès G. Oncotarget **2016**
- 9. p120RasGAP mediates ephrin/Eph-dependent attenuation of FGF/ERK signals during cell fate specification in ascidian embryos.** Haupaix N, Stolfi A, Sirour C, Picco V, Levine M, Christiaen L, Yasuo H. Development **2013**
- 10. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.** Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E. Nat Cell Biol **2013**
- 11. ephrin-Eph signalling drives the asymmetric division on notochord/neural precursors in *Ciona* embryos.** Picco V., Hudson C., Yasuo Y. Development **2007**

PATENT

Method for individualized cancer therapy. Picco V, Pagès G. BREVET EP3325971 **2017**

REVIEW ARTICLES

12. The telomere proteins in tumorigenesis and clinical outcomes of oral squamous cell carcinoma. Benhamou Y *, Picco V *, Pagès G. Oral Oncology **2016**.

13. Linking JNK Activity to the DNA Damage Response. Picco V, Pagès G. Genes and Cancer **2013**

Corresponding author

*** Equal contribution**